Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director
|
|
IMPAX LABORATORIES INC (IPXL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2019 |
SC 13G/A
| MAVERICK CAPITAL LTD reports a 0% stake in IMPAX LABORATORIES, INC. |
| 02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/07/2018 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 05/10/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 05/08/2018 |
4
| Vergis Janet S. (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 6,642 shares
@ $0
Disposed/sold 5,508 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 8,100 options to buy
@ $38.42, valued at
$311.2k
|
|
| 05/08/2018 |
4
| TERRERI PETER R (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 43,129 shares
@ $0
Disposed/sold 5,408 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 7,300 options to buy
@ $44.85, valued at
$327.4k
Disposed/sold 11,500 options to buy
@ $25.24, valued at
$290.3k
Disposed/sold 12,000 options to buy
@ $17.99, valued at
$215.9k
Disposed/sold 10,000 options to buy
@ $20.9, valued at
$209k
Disposed/sold 10,000 options to buy
@ $27.97, valued at
$279.7k
Disposed/sold 10,000 options to buy
@ $20.3, valued at
$203k
Disposed/sold 45,000 options to buy
@ $6.55, valued at
$294.8k
|
|
| 05/08/2018 |
4
| PENDERGAST MARY K (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 16,942 shares
@ $0
Disposed/sold 5,408 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 7,300 options to buy
@ $44.85, valued at
$327.4k
Disposed/sold 11,500 options to buy
@ $25.24, valued at
$290.3k
Disposed/sold 12,000 options to buy
@ $20.36, valued at
$244.3k
|
|
| 05/08/2018 |
4
| CHAO ALLEN (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 64,037 shares
@ $0
Disposed/sold 20,000 shares
@ $0
Disposed/sold 180,000 shares
@ $0
Disposed/sold 116,000 shares
@ $0
Disposed/sold 5,408 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 7,300 options to buy
@ $44.85, valued at
$327.4k
Disposed/sold 11,500 options to buy
@ $25.24, valued at
$290.3k
Disposed/sold 12,000 options to buy
@ $17.99, valued at
$215.9k
Disposed/sold 10,000 options to buy
@ $20.9, valued at
$209k
|
|
| 05/08/2018 |
4
| BUCHI J KEVIN (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 8,020 shares
@ $0
Disposed/sold 3,281 shares
@ $0
Disposed/sold 7,931 options to buy
@ $16.4, valued at
$130.1k
Disposed/sold 20,445 options to buy
@ $14.45, valued at
$295.4k
|
|
| 05/08/2018 |
4
| BENET LESLIE Z (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 17,741 shares
@ $0
Disposed/sold 600 shares
@ $0
Disposed/sold 4,742 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 12,000 options to buy
@ $44.85, valued at
$538.2k
Disposed/sold 2,750 options to buy
@ $35.89, valued at
$98.7k
Disposed/sold 19,600 options to buy
@ $25.24, valued at
$494.7k
Disposed/sold 25,000 options to buy
@ $17.99, valued at
$449.8k
Disposed/sold 16,000 options to buy
@ $20.9, valued at
$334.4k
Disposed/sold 19,000 options to buy
@ $27.97, valued at
$531.4k
|
|
| 05/08/2018 |
4
| BURR ROBERT L (Director) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 55,067 shares
@ $0
Disposed/sold 6,057 shares
@ $0
Disposed/sold 5,408 shares
@ $0
Disposed/sold 10,575 options to buy
@ $16.4, valued at
$173.4k
Disposed/sold 10,575 options to buy
@ $30.33, valued at
$320.7k
Disposed/sold 7,300 options to buy
@ $44.85, valued at
$327.4k
Disposed/sold 11,500 options to buy
@ $25.24, valued at
$290.3k
Disposed/sold 12,000 options to buy
@ $17.99, valued at
$215.9k
Disposed/sold 10,000 options to buy
@ $20.9, valued at
$209k
Disposed/sold 10,000 options to buy
@ $27.97, valued at
$279.7k
Disposed/sold 10,000 options to buy
@ $20.3, valued at
$203k
|
|
| 05/08/2018 |
4
| Nornhold Jeffrey (SVP, Technical Operations) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 54,043 shares
@ $0
Disposed/sold 11,835 shares
@ $0
Disposed/sold 41,842 options to buy
@ $9.35, valued at
$391.2k
Disposed/sold 41,842 options to buy
@ $33.27, valued at
$1.4M
Disposed/sold 28,500 options to buy
@ $40.7, valued at
$1.2M
Disposed/sold 55,000 options to buy
@ $25.24, valued at
$1.4M
|
|
| 05/08/2018 |
4
| SCHLOSSBERG MARK A (SVP and General Counsel) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 50,116 shares
@ $0
Disposed/sold 18,135 shares
@ $0
Disposed/sold 56,232 options to buy
@ $9.35, valued at
$525.8k
Disposed/sold 52,801 options to buy
@ $33.27, valued at
$1.8M
Disposed/sold 47,500 options to buy
@ $40.7, valued at
$1.9M
Disposed/sold 55,000 options to buy
@ $25.24, valued at
$1.4M
Disposed/sold 52,000 options to buy
@ $17.99, valued at
$935.5k
Disposed/sold 21,667 options to buy
@ $20.9, valued at
$452.8k
Disposed/sold 100,000 options to buy
@ $21.24, valued at
$2.1M
|
|
| 05/08/2018 |
4
| NESTOR MICHAEL (President, Impax Specialty) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 56,796 shares
@ $0
Disposed/sold 19,728 shares
@ $0
Disposed/sold 56,232 options to buy
@ $9.35, valued at
$525.8k
Disposed/sold 52,801 options to buy
@ $33.27, valued at
$1.8M
Disposed/sold 47,500 options to buy
@ $40.7, valued at
$1.9M
Disposed/sold 55,000 options to buy
@ $25.24, valued at
$1.4M
Disposed/sold 52,000 options to buy
@ $17.99, valued at
$935.5k
Disposed/sold 32,500 options to buy
@ $20.9, valued at
$679.3k
Disposed/sold 32,500 options to buy
@ $27.97, valued at
$909k
Disposed/sold 32,500 options to buy
@ $20.3, valued at
$659.8k
Disposed/sold 16,250 options to buy
@ $6.55, valued at
$106.4k
|
|
| 05/08/2018 |
4
| Boothe Douglas (President, Generics Division) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 14,145 shares
@ $0
Disposed/sold 41,756 shares
@ $0
Disposed/sold 50,500 options to buy
@ $24.42, valued at
$1.2M
Disposed/sold 56,232 options to buy
@ $9.35, valued at
$525.8k
|
|
| 05/08/2018 |
4
| Reasons Bryan M. (CFO) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 53,423 shares
@ $0
Disposed/sold 20,566 shares
@ $0
Disposed/sold 56,232 options to buy
@ $9.35, valued at
$525.8k
Disposed/sold 63,095 options to buy
@ $33.27, valued at
$2.1M
Disposed/sold 47,500 options to buy
@ $40.7, valued at
$1.9M
Disposed/sold 55,000 options to buy
@ $25.24, valued at
$1.4M
Disposed/sold 52,000 options to buy
@ $17.99, valued at
$935.5k
|
|
| 05/08/2018 |
4
| BISARO PAUL (President and CEO) has filed a Form 4 on Impax Laboratories, LLC|
Txns:
| Disposed/sold 850,000 options to buy
@ $12.7, valued at
$10.8M
|
|
| 05/07/2018 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 05/07/2018 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 7, 2018 IMPAX LABORATORIES, LLC Delaware 001-34263 65-0403311 30831 Huntwood Avenue, Hayward, CA 94544 240-6000 Registrant's telephone number, including area code Impax Laboratories, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Form of Amended and Restated Certificate of Incorporation of Impax Laboratories, Inc",
"Form of Amended and Restated Bylaws of Impax Laboratories, Inc",
"Limited Liability Company Agreement of Impax Laboratories, LLC",
"Second Supplemental Indenture",
"Term Loan Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and other parties party thereto",
"Revolving Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, the other loan parties from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent and the lenders and other parties party thereto",
"Term Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Revolving Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Termination Agreement, , between Impax Laboratories, LLC (f/k/a Impax Laboratories, Inc.) and Royal Bank of Canada" |
|
| 05/04/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/30/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/13/2018 |
10-K/A
| Annual Report for the period ended December 31, 2017 [amend] |
| 04/10/2018 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.1% stake in Impax Laboratories Inc |
| 04/05/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 03/27/2018 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 03/19/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/19/2018 |
8-K
| Other Events |
| 03/15/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/07/2018 |
8-K
| Regulation FD Disclosure |
| 03/05/2018 |
4
| Nornhold Jeffrey (SVP, Technical Operations) has filed a Form 4 on IMPAX LABORATORIES INC|
Txns:
| Paid exercise price by delivering 2,436 shares
@ $19.5, valued at
$47.5k
|
|
| 03/05/2018 |
4
| Boothe Douglas (President, Generics Division) has filed a Form 4 on IMPAX LABORATORIES INC|
Txns:
| Paid exercise price by delivering 2,041 shares
@ $19.5, valued at
$39.8k
|
|
| 03/05/2018 |
4
| SCHLOSSBERG MARK A (SVP and General Counsel) has filed a Form 4 on IMPAX LABORATORIES INC|
Txns:
| Paid exercise price by delivering 3,273 shares
@ $19.5, valued at
$63.8k
|
|
| 03/05/2018 |
4
| Reasons Bryan M. (CFO) has filed a Form 4 on IMPAX LABORATORIES INC|
Txns:
| Paid exercise price by delivering 3,069 shares
@ $19.5, valued at
$59.8k
|
|
| 03/02/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|
|
|